Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CVL-865 in Drug-Resistant Focal Onset Seizures
NCT04244175Phase 2Completed
- Sponsor
- AbbVie Inc.
- Start
- Jan 2020
- Primary completion
- May 2024
- Modality
- Small Molecules
- Countries
- 7
01
Overview
A Phase 2 trial of darigabat in focal-onset epilepsy, sponsored by AbbVie Inc.. Started Jan 2020; status: completed.
02
Drugs
darigabat
03
Conditions
focal-onset epilepsy
Beyond the preview
Go deeper on NCT04244175.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04244175.